SEC Form 4 · accession 0001209191-16-113982

aTYR PHARMA INC · LIFE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Director

Period of report

Apr 11, 2016

Accepted (ET)

Apr 12, 2016 · 3:57 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001339970

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Apr 11, 2016	P	27,359	$3.5915	A	214,931	D
Common Stock^F2	Apr 11, 2016	P	5,300	$3.4481	A	220,231	D
Common Stock^F3	holding	—	—		—	634,242	I	See Footnote
Common Stock^F4	holding	—	—		—	31,181	I	See Footnote

No Table II lines on this filing.

F1Represents the weighted average price for the shares. The shares were purchased at prices ranging from $3.58 per share to $3.60 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
F2Represents the weighted average price for the shares. The shares were purchased at prices ranging from $3.44 per share to $3.45 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
F3These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000.
F4These shares are owned directly by Paul R. Schimmel Prototype PSP. The Reporting Person is the trustee of the Paul R. Schimmel Prototype PSP.